Your browser doesn't support javascript.
loading
Split dose ATG strategy prevents grade III-IV acute GVHD and is associated with immune surrogates of GVL.
Al-Kadhimi, Zaid; Pirruccello, Samuel; Gul, Zartash; Maness-Harris, Lori; Bhatt, Vijaya Raj; Gundabolu, Krishna; Yuan, Jane; Lunning, Matthew; Bociek, Gregory; D'Angelo, Christopher; Kallam, Avyakta; Armitage, James; Abdullah, Khansa; Hunter, Angela; Mccaslin, Sarah; Lyden, Elizabeth; Smith, Lynnette; Callahan, Michael; Cole, Kathryn; Hinrichs, Steven; Talmadge, James; Vose, Julie.
Afiliación
  • Al-Kadhimi Z; Division of Hematology & Oncology, University of Nebraska Medical Center, Omaha, NE, USA. zaid.alkadhimi@unmc.edu.
  • Pirruccello S; Department of Pathology & Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Gul Z; Division of Hematology/Oncology, Aurora Health Care, Milwaukee, WI, USA.
  • Maness-Harris L; Division of Hematology & Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Bhatt VR; Division of Hematology & Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Gundabolu K; Division of Hematology & Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Yuan J; Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, NY, USA.
  • Lunning M; Division of Hematology & Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Bociek G; Division of Hematology & Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
  • D'Angelo C; Division of Hematology & Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Kallam A; Division of Hematology & Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Armitage J; Division of Hematology & Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Abdullah K; Division of Hematology & Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Hunter A; Division of Hematology & Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Mccaslin S; Division of Hematology & Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Lyden E; Division of Biostatistics, University of Nebraska Medical Center, Omaha, NE, USA.
  • Smith L; Division of Biostatistics, University of Nebraska Medical Center, Omaha, NE, USA.
  • Callahan M; Division of Hematology & Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Cole K; Department of Pathology & Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Hinrichs S; Department of Pathology & Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Talmadge J; Department of Pathology & Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Vose J; Division of Hematology & Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Bone Marrow Transplant ; 57(10): 1629-1631, 2022 10.
Article en En | MEDLINE | ID: mdl-35953707
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Enfermedad Injerto contra Huésped Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Enfermedad Injerto contra Huésped Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido